FREE TO MOVE is more than just our comprehensive joint health portfolio. It’s how we want every horse to feel.
Learn more about degenerative joint disease, and discover our full joint health product portfolio at the link below.
First and only FDA-approved hyaluronic acid joint therapy currently available for both intravenous and intra-articular administration.
LEGEND Injectable Solution is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis. Equine osteoarthritis can happen in any age and any discipline due to everyday wear and tear. It is permanent and can lead to early retirement and quality-of-life issues in horses.
The active ingredient in LEGEND, hyaluronic acid (HA), decreases the presence of inflammatory mediators in the joint, improves synovial fluid quality, and reduces the degree of lameness. These improvements are seen whether LEGEND is administered by intravenous (I.V.) or intra-articular (I.A.) injection. LEGEND hyaluronate sodium injectable is sterile, pyrogen-free and FDA-approved.
Not for use in humans. Keep this and all other drugs out of reach of children. The safety of LEGEND has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares. LEGEND 4 mL and LEGEND Multi-Dose Injectable Solution are administered by intravenous injection only.
Millions of doses sold, more than 25 years of treatment success, safe and efficacious, proven by multiple studies
Reduces production of inflammatory mediators, joint inflammation and the resulting lameness for at least 45 days after being given once a week for three weeks.4
FDA approved joint therapy for both I.V. and I.A. administration, so you can choose the treatment to meet your horse’s need
Safe and efficacious
90% of cases treated I.V. judged to have excellent to good overall clinical improvement1
96% of horses treated intra-articularly were judged to have excellent to good overall clinical improvement1
Improvement can be seen after one dose
Provides multi-modal approach against the cycle of inflammation and lameness
Stimulates endogenous hyaluronic acid production2
Creates a physical barrier to exclude inflammatory mediators3
Decreases the presence of inflammatory mediators4
Easy to use I.V. administration for when intra-articular administration is not practical or desired
LEGEND can only be used by or on the order of a veterinarian.
LEGEND Multi Dose (20 mL) and LEGEND 4 mL (40 mg) can be injected intravenously only at a dosage of 4 mL. Intravenous treatment may be repeated at weekly intervals for a total of 3 treatments. LEGEND 2 mL (20 mg) can be injected intravenously (at a dosage of 4 mL) or intra-articularly in the carpus or fetlock.
Not for use in humans. Keep this and all other drugs out of reach of children.
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For use only in horses. Do not use in horses intended for human consumption.
LEGEND 4 mL and LEGEND Multi-dose 20 mL are approved only for I.V. use. LEGEND 2 mL is approved for I.V. and I.A. use. The intra-articular safety of LEGEND Multi Dose 20 mL with benzyl alcohol has not been evaluated.
The safety of LEGEND has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares.
The following adverse reactions have been reported following use of LEGEND Injectable Solution: Following intravenous use: occasional depression, lethargy, and fever. Following intra-articular (LEGEND Injectable Solution — 2 mL only) use: lameness, joint effusion, joint or injection site swelling and joint pain.
Not for use in humans. Keep this and all other drugs out of reach of children. Strict aseptic techniques should be observed when administering by intra-articular injection.
Store at or below 77° F (25° C). Brief excursions to 104° F (40° C) are permitted.
A blinded clinical study compared the treatment effectiveness of I.V. or I.A. administration of LEGEND in 46 horses. All groups showed significant improvement. LEGEND-administered I.V. had no statistical difference in any of the measured parameters from LEGEND-administered I.A.1
1 LEGEND Product Label
2 Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int 1987;7(3):113–222.
3 McIlwraith CW. Traumatic joint disease. Orthopaedic Research Center, Colorado State University website http://csu-cvmbs.colostate.edu/academics/clinsci/equine-orthopaedic-research-center/orthopaedic-topics/Pages/traumatic-joint-disease.aspx#legend. Accessed July 31, 2015.
4 Kawcak CE, Frisbie DD, Trotter GW, et al. Effects of intravenous administration of sodium hyaluronate on carpal joints in exercising horses after arthroscopic surgery and osteochondral fragmentation. Am J Vet Res 1997;58(10):1132–1140.
LEGEND® is a registered trademark and the Horse logo™ is a trademark of Boehringer Ingelheim Animal Health USA Inc. ©2024 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0115-2021-V2
The safety of LEGEND has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares. The following adverse reactions have been reported following use of LEGEND Injectable Solution: Following intravenous use: occasional depression, lethargy and fever. Following intra-articular (LEGEND Injectable Solution–2 mL only) use: lameness, joint effusion, joint or injection site swelling, and joint pain. LEGEND 4 mL and LEGEND Multi-Dose Injectable Solution are administered by intravenous injection only.